Literature DB >> 17393410

In vitro studies of steroid hormones in neurofibromatosis 1 tumors and Schwann cells.

Lauren Fishbein1, Xuelian Zhang, Lori B Fisher, Hua Li, Martha Campbell-Thompson, Anthony Yachnis, Allan Rubenstein, David Muir, Margaret R Wallace.   

Abstract

The most common NF1 feature is the benign neurofibroma, which consists predominantly of Schwann cells. Dermal neurofibromas usually arise during puberty and increase in number throughout adulthood. Plexiform neurofibromas, associated with larger nerves, are often congenital and can be life threatening. Malignant peripheral nerve sheath tumors (MPNST) in NF1 are believed to arise from plexiforms in 5%-10% of patients. There are reports of increased potential for malignant transformation of plexiform tumors and increase in dermal neurofibromas, during pregnancy. These observations suggest that steroid hormones influence neurofibroma growth, and our work is the first to examine steroid hormone receptor expression and ligand-mediated cell growth and survival in normal human Schwann cells and neurofibroma-derived Schwann cell cultures. Immunohistochemistry and real-time PCR showed that estrogen receptors (ERs), progesterone receptor (PR), and androgen receptor are differentially expressed in primary neurofibromas and in NF1 tumor-derived Schwann cell cultures compared to normal Schwann cells. However, there is substantial heterogeneity, with no clear divisions based on tumor type or gender. The in vitro effects of steroid hormone receptor ligands on proliferation and apoptosis of early passage NF1 tumor-derived Schwann cell cultures were compared to normal Schwann cell cultures. Some statistically significant changes in proliferation and apoptosis were found, also showing heterogeneity across groups and ligands. Overall, the changes are consistent with increased cell accumulation. Our data suggest that steroid hormones can directly influence neurofibroma initiation or progression by acting through their cognate receptor, but that these effects may only apply to a subset of tumors, in either gender. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393410     DOI: 10.1002/mc.20236

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  16 in total

1.  Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.

Authors:  Stephanie J Byer; Jenell M Eckert; Nicole M Brossier; Buffie J Clodfelder-Miller; Amy N Turk; Andrew J Carroll; John C Kappes; Kurt R Zinn; Jeevan K Prasain; Steven L Carroll
Journal:  Neuro Oncol       Date:  2010-11-12       Impact factor: 12.300

2.  The effect of estradiol, testosterone, and human chorionic gonadotropin on the proliferation of Schwann cells with NF1 +/- or NF1 -/- genotype derived from human cutaneous neurofibromas.

Authors:  Paula Pennanen; Sirkku Peltonen; Roope A Kallionpää; Juha Peltonen
Journal:  Mol Cell Biochem       Date:  2017-11-28       Impact factor: 3.396

Review 3.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

4.  Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells.

Authors:  Hua Li; Xuelian Zhang; Lauren Fishbein; Frederick Kweh; Martha Campbell-Thompson; George Q Perrin; David Muir; Margaret Wallace
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

5.  Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.

Authors:  Urania Dagalakis; Maya Lodish; Eva Dombi; Ninet Sinaii; Jessica Sabo; Andrea Baldwin; Seth M Steinberg; Constantine A Stratakis; Brigitte C Widemann
Journal:  J Pediatr       Date:  2013-12-08       Impact factor: 4.406

6.  Expression analysis of genes lying in the NF1 microdeletion interval points to four candidate modifiers for neurofibroma formation.

Authors:  B Bartelt-Kirbach; M Wuepping; M Dodrimont-Lattke; D Kaufmann
Journal:  Neurogenetics       Date:  2008-10-11       Impact factor: 2.660

7.  Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades.

Authors:  Stephanie N Brosius; Amy N Turk; Stephanie J Byer; Jody Fromm Longo; John C Kappes; Kevin A Roth; Steven L Carroll
Journal:  J Neuropathol Exp Neurol       Date:  2014-11       Impact factor: 3.685

8.  Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression.

Authors:  Nathaniel Alzofon; Katrina Koc; Kristin Panwell; Nikita Pozdeyev; Carrie B Marshall; Maria Albuja-Cruz; Christopher D Raeburn; Katherine L Nathanson; Debbie L Cohen; Margaret E Wierman; Katja Kiseljak-Vassiliades; Lauren Fishbein
Journal:  Mol Cancer Res       Date:  2021-05-13       Impact factor: 5.852

9.  Progesterone and Estrogen Receptors in Neurofibromas of Patients with NF1.

Authors:  Mauro Geller; Spyros G E Mezitis; Fabio Pereira Nunes; Marcia G Ribeiro; Alexandra Prufer de Q C Araújo; Marcello D Bronstein; Rodrigo Siqueira-Batista; Andréia Patrícia Gomes; Lisa Oliveira; Karin Soares Gonçalves Cunha
Journal:  Clin Med Pathol       Date:  2008-09-15

10.  Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research.

Authors:  Deeann Wallis; Anat Stemmer-Rachamimov; Sarah Adsit; Bruce Korf; Dominique Pichard; Jaishri Blakeley; Kavita Y Sarin
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.